Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review.
10.7534/j.issn.1009-2137.2018.02.048
- Author:
Wen-Jing FAN
1
,
2
;
Zhi-Qiao FAN
3
;
Tao WU
4
;
Hai BAI
3
Author Information
1. Center of Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Province, China
2. The Second Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
3. Center of Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Province, China.
4. Center of Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Province, China. E-mail: wutaozhen@yeah.net.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Humans;
Lenalidomide;
Leukemia, Lymphocytic, Chronic, B-Cell;
Lymphoma, Non-Hodgkin;
Multiple Myeloma;
Thalidomide;
analogs & derivatives;
pharmacology
- From:
Journal of Experimental Hematology
2018;26(2):595-599
- CountryChina
- Language:Chinese
-
Abstract:
Lenalidomide, a novel immunomodulatory agent, is a kind of thalidomide derivatives, which shows a good efficacy and safety for hematological system diseases. This review is aimed to evaluate the efficacy and safety of lenalidomide in treatment of patients with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, classical Hodgkin's lymphoma and POEMS syndrome at their replased or refractory state. At the same time, this review focuses on the newest clinical research and the latest application progress of lenalidomide for relapsed or refractory hematological system diseases.
